3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
161
Neoplasm Metastasis
22
Neoplasms
20
Advanced Breast Cancer
13
Ovarian Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Hereditary Sensory and Autonomic Neuropathies
9
Endometrial Neoplasms
8
Triple Negative Breast Neoplasms
7
Colorectal Neoplasms
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Prostatic Neoplasms
5
Recurrence
4
Neoplasms by Site
4
Multiple Endocrine Neoplasia Type 1
4
Breast Diseases
4
Small Cell Lung Carcinoma
3
Head and Neck Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Uterine Neoplasms
2
Stomach Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Liposarcoma
2
HER2-positive Metastatic Breast Cancer
2
Advanced Solid Tumors
2
Advanced Solid Tumor
2
Urologic Neoplasms
1
Interventions
pembrolizumab
8
Pemetrexed
8
capmatinib
7
Carboplatin
7
ceritinib
5
Cisplatin
5
Bevacizumab
4
Docetaxel
3
trametinib
2
motexafin gadolinium
2
aldesleukin
2
Vinorelbine
2
Paclitaxel
2
Interleukin-2
2
Gefitinib
2
BID protein, human
2
technetium 99m etarfolatide
1
spartalizumab
1
sintilimab
1
satraplatin
1
ribociclib
1
picropodophyllin
1
nazartinib
1
naporafenib
1
milademetan
1
lazertinib
1
fludarabine phosphate
1
fludarabine
1
farletuzumab
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma of Lung
×
Fulvestrant
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled